Combination chemotherapy of gemcitabine and cisplatin by double way plus implantation of radioactive seed 125I in treating stage Ⅲ non-small cell lung cancer

Objective To assess the therapeutic effect of combination chemotherapy of gemcitabine and cisplatin by double way plus implantation of radioactive seed 125I implantation in treating stage Ⅲ non-small cell lung cancer. Methods Sixty cases with stage Ⅲ non-small cell lung cancer were randomly divided into two groups with random number table. In group A (in interventional treatment group, n = 30),the gemcitabine 1000 mg/m2 and one third of the cisplatin 100 mg/m2 was given using seldinger technique for transcatheter bronchial arterial infusion chemotherapy on day 1. Two-thirds of the cisplatin 100 mg/m2 was infused in veins on day 2 and 3. The gemcitabine 1000 mg/m2 was infused in veins on day 8, 21 days for a period. In group B (interventional - 125I groups), the method of combination chemotherapy of gemcitabine and cisplatin was the same as in Group A. After ten days of arterial perfusion, 125I seeds were implantated, 21 days for a period. All patients received at least 2 cycles. The imaging evaluation of patients after treatment standards included complete remission (CR), partial remission (PR), stable (SD),progressive disease (PD), effective rate (CR + PR)/30 and clinical benefit rate (CR + PR + SD)/30.Non-parametric rank sum test was used to compare short-term effect of the two groups treatment of two cycles.x2 test was used to compare year survival, Kaplan-Meier method was used to calculate median survival,log-rank test method was used to difference between the groups. Results In group A, there were 17 PR,9SD and 4 PD. The overall response rate was 56. 7% (17/30) and clinical beneficial rate was 86. 7% (26/30). In Group B, there were 2 CR, 21 PR, 7 SD. The overall response rate was 76.7% (23/30) and clinical beneficial rate was 100% (30/30). There was significant difference between the two groups (P =0. 036). In group A, the 1 year survival rate was 46. 7% (14/30) and the 2 year survival rate was 36. 7%(11/30), median survival time (MST) was 10 months . In group B, the 1 year survival rate was 76. 7%(23/30) and the 2 year survival rate was 63. 3% (19/30) , median survival time (MST) was 27 months.There was a significant difference between two group in 1 year survival rate (P = 0. 017), 2 year survival rate (P = 0. 039) and median survival time (P = 0. 006). Conclusion The treatment effects of Ⅲ stage non-small cell lung cancer by gemcitabine and cisplatin combination chemotherapy with double way plus radioactive seed 125I implantation was better than gemcitabine and cisplatin combination chemotherapy with double way.     

可溶性细胞间黏附分子-1在矽肺患者血清中的表达

应用酶联免疫吸附试验分别检测100例非矽肺接尘工人,54例Ⅰ期矽肺患者血清中可溶性细胞间黏附分子-1(sICAM-1)的含量.经成组设计:检验,两组研究对象在年龄及接尘工龄上,差异无统计学意义(P>0.05),sICAM-1的含量在Ⅰ期矽肺患者血清中显著高于非矽肺接尘工人(P<0.05).提示sICAM-1可能是参与矽肺发生发展的重要免疫指标,且在矽肺形成早期即呈现高表达.     

吉西他滨热化疗灌注联合TAE治疗原发性肝细胞癌

目的 探讨吉西他滨热化疗灌注联合TAE治疗原发性肝细胞癌（PHCC）的价值。方法 将96例PHCC患者随机分为2组,A组采用热化疗灌注与TAE联合治疗,B组采用常温下化疗灌注与TAE联合治疗;比较治疗前、治疗后3天及30天肝、肾功能变化,治疗前、治疗后7天免疫功能变化;治疗后30天行CT平扫和多期增强扫描,依据RECIST标准比较两组临床有效率;每间隔30天重复治疗1次,第3次介入治疗后进行随访,比较两组总生存期。结果 治疗后3天A、B两组丙氨酸转氨酶（ALT）及谷草转氨酶（AST）较治疗前均升高（P〈0.05）,且B组高于A组（P〈0.01）,但治疗后30天较治疗前无变化,而A、B两组肾功能治疗前后无明显变化。近期疗效评价A组临床有效率75.00%（36/48）,B组39.58%（19/48）,两组差异有统计学意义（P〈0.01）;A组治疗后免疫功能提高,而B组治疗后下降。A组中位生存时间为24.0个月,B组中位生存时间为19.0个月（P〈0.01）。结论 热化疗灌注联合TAE是治疗PHCC的有效方法,且对肝功能影响仅为一过性的。     

经皮经肝胆道引流术后感染的临床观察

目的:了解引起经皮经肝胆道引流(PTCD)术后感染致病菌的分布情况,并比较血液细菌培养和胆汁细菌培养在检出致病菌上的差异。方法:对2年来31例梗阻性黄疸患者在PTCD术后感染时分别采集血液和胆汁,并进行细菌培养及药敏测试。结果:31份胆汁中有29份标本培养出细菌,阳性检出率为93.5%;共培养出细菌37株,其中革兰阴性杆菌24株(64.9%),革兰阳性球菌8株(21.6%),真菌5株(13.5%)。革兰阴性杆菌对亚安培南/西司他叮的敏感率最高,为92.3%,其次为头孢哌酮/舒巴坦、头孢吡肟,敏感率分别为84.6%、84.6%。革兰阳性球菌对万古霉素的敏感率为100.0%,丁胺卡那霉素92.3%敏感。结论:胆道感染病原菌以革兰阴性杆菌为主,胆汁细菌培养阳性率显著高于血细菌培养。     

乳腺癌术后三苯氧胺致脂肪肝36例分析

目的:分析口服三苯氧胺导致脂肪肝的CT表现和发生机制.提高对三苯氧胺治疗乳腺癌不良反应的认识.方法:回顾性分析36例乳腺癌术后口服三苯氧胺致脂肪肝患者的CT及临床资料.结果:36例脂肪肝患者中,轻度脂肪肝20例(55.5%),中度脂肪肝11例(30.6%),重度脂肪肝5例(13.9%);以CT表现分型:弥漫性脂肪肝31例(86.1%),局灶性脂肪肝5例(13.9%);治疗过程中36例患者有6例(16.7%)出现转氨酶升高,其中4例停药后复查,肝功能均正常:8例停药后复查的脂肪肝患者中6例好转,2例恢复正常.结论:苯氧胺可诱导脂肪肝的发生,以轻度弥漫性脂肪肝最为多见,临床医生应认识到这种副作用,早期诊断,及时治疗.     

左锁骨下动脉双管同时置入治疗直肠癌肝转移疗效观察

目的探讨治疗直肠癌伴肝转移的新方法。方法对11例直肠癌伴肝转移患者行左锁骨下动脉双管置入,行规律动脉化疗。结果11例患者中,8例存活2年以上,2年生存率为72.7%,效果令人满意。结论动脉双管置入对于直肠癌伴有肝转移者疗效明确。     

铅对作业工人甲状腺功能的影响

目的　了解铅对作业工人甲状腺功能的影响。方法　选择暴露于铅作业环境下的人群 ,了解工人作业工龄 ,采用火焰原子吸收光谱法测定其作业环境中铅浓度 ,用原子吸收光谱法测定作业工人血铅 (PbB)浓度 ,用血液锌原卟啉测定仪测定血锌原卟啉 (ZPP)浓度 ,用放射免疫分析法检测血清中促甲状腺素 (TSH)、三碘甲状腺原氨酸 (T3)、甲状腺素 (T4 )、游离T3(FT3)、游离T4 (FT4 ) 5项甲状腺功能指标。结果　血铅 >2 .88μmol/L时 ,T3[(1 .54± 0 .39)nmol/L]、FT3[(5 .50± 1 .2 6)pmol/L]含量明显低于血铅 (1 .92～ 2 .88) μmol/L组 [T3(1 .71± 0 .45)nmol/L、FT3(6 .1 2± 1 .64)pmol/L] ,差异有显著性(P <0 .0 5)。铅作业工龄长短对甲状腺激素 (TH)含量未见明显影响。结论　高浓度血铅可能抑制了T4 的脱碘 ;铅作业工龄对甲状腺功能未见明显影响     

全程CT引导下经皮穿刺胃造瘘的临床应用

目的 探讨全程CT引导下经皮穿刺胃造瘘的临床应用价值.方法 2012年12月至2014年12月,共15例因食管完全性梗阻、复杂食管纵隔气管瘘患者及严重心脏疾病的患者无法经口插管至胃内充气,采用全程CT引导下使用21G穿刺针穿刺至胃内进行充气,然后将胃壁固定至腹壁,使用T型针穿刺胃壁建立胃造瘘通道,经可撕脱鞘置入带球囊的胃造瘘管,充盈球囊,移除可撕脱鞘,完成胃造瘘.结果 所有患者均在全程CT引导下完成胃造瘘治疗,治疗成功率达到100％,医生操作时间平均31 min.随访期间无严重并发症如腹膜炎、胃结肠瘘及大出血发生,轻微并发症出现6例.3例造瘘口局部感染伴严重肉芽组织增生,经局部清创及消毒换药后痊愈;2例造瘘口食物外渗,更换更粗的胃造瘘管(17G)并重新固定后外渗停止;1例患者在2个月时出现造瘘管脱落,当即返回医院后更换胃造瘘管成功.结论 全程CT引导下胃造瘘技术成功率高,并发症轻微,可作为一种有效的治疗手段应用于临床患者.     

艾迪持续动脉灌注联合栓塞治疗伴有肝细胞黄疸的肝脏恶性肿瘤

目的观察艾迪持续动脉灌注联合栓塞治疗伴有肝细胞黄疸的肝脏恶性肿瘤的临床疗效。方法对49例伴有肝细胞黄疸的原发肝癌和肝转移癌患者经左锁骨下动脉留置导管内灌注艾迪注射液并进行栓塞治疗。结果49例患者中,有1例死亡;2例中途放弃治疗,共46例完成治疗。0.5、1、2、3年生存率为89.1%（41/46）,34.8%（16/46）,17.4%（8/46）,4.3%（2/46）。结论对于伴有肝细胞黄疸的原发肝癌和肝转移癌患者,使用艾迪持续动脉灌注联合栓塞可以在改善肝功能的前提下,有效的控制肿瘤,同时提高患者的免疫功能和生存率。     

原发性肝癌CT灌注成像与微血管密度关系的研究

目的探讨原发性肝细胞癌(HCC)CT灌注成像与肿瘤内微血管密度(MVD)的关系。方法选择17例行肝穿刺活检病理证实为原发性肝细胞癌(HCC)的患者。在行肝穿活检前均行CT灌注成像。活检后送病理科采用LSAB免疫组化法检测其MVD。结果肿瘤强化越明显,其相应的肿瘤MVD计数越多,肿瘤强化与相应的MVD呈正相关。结论原发性肝细胞癌CT增强幅度与其MVD值有密切关系,可用于评价肿瘤的恶性程度。